In 2020, the global peripheral vascular device market size was valued at $11.9 billion, with over 16 million yearly peripheral vascular procedures performed. The market size is expected to increase at a compound annual growth rate (CAGR) of 5.2% to reach $16.9 billion in 2026. Throughout this medical market research, we analyzed 113 peripheral vascular

In 2020, the European peripheral vascular device market size was valued at about €1.3 billion, with over 1.15 million peripheral vascular procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 2.9% to reach €1.6 billion in 2026. Throughout this medical market research, we analyzed 65

In 2020, the U.S. peripheral vascular device market size was valued at $7.1 billion, with over 8.26 million peripheral vascular procedures performed each year. The market size is expected to increase and reach $10.4 billion by 2026. Throughout this medical market research, we analyzed 67 peripheral vascular companies across the United States and used our comprehensive

The transcatheter embolization market is segmented into four types of devices: particle embolics, coil embolics, liquid embolics and vascular plugs. Detachable balloons are also used for embolization procedures, but are not covered in this report because they are rarely used.

Transcatheter embolization is the practice of introducing material to within the vasculature to induce blood flow occlusions. Transcatheter embolization is effective for treating vessel malformations such as aneurysms, fistulae and bleeding. If left untreated, some of these arteriovenous malformations can ultimately lead to strokes. In addition, transcatheter embolization is an effective therapy for blocking blood flow to tumors or organs, thus starving the target tissues. Specialized particles, such as drug-coated and radiolabeled beads, are used for the targeted delivery of drugs and for radiation therapy, respectively.

The full report suite on the European market for Peripheral Vascular (PV) devices includes peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion (CTO) devices, embolic protection devices (EPDs), stent-grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, diagnostic and interventional catheters, standard and hydrophilic guidewires, introducer sheaths, vascular closure devices (VCDs) and transcatheter embolization devices.

The Chinese market for peripheral vascular devices includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, embolic protection devices, stent grafts, surgical grafts, inferior vena cava filters, diagnostic and interventional catheters, diagnostic and interventional guidewires, introducer sheaths and vascular closure devices. Several of these devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those used for peripheral procedures are included in this report. As a result of a general increase in peripheral procedures and their relatively low cost, the market for PTA balloons will grow rapidly in China over the 2011–2018 forecast period.

The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, embolic protection devices, stent grafts, surgical grafts, IVUS catheters, inferior vena cava filters, diagnostic and interventional catheters, diagnostic and interventional guidewires, introducer sheaths and vascular closure devices. Several of these devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As a result of the general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as atherectomy devices is expected to grow rapidly in Japan over the 2011–2018 forecast period.